メインコンテンツにスキップ
検索

AIの力を医薬品開発プロジェクトに導入:MBMAおよびCODEx臨床試験成績データベースを用いた実施か中止かの決定

The top challenge today for life sciences and healthcare organizations is effectively extracting and operationalizing information from complex sources for decision-making. Certara’s deep-learning platform and model based meta-analysis (MBMA) services offer integrated solutions for researchers seeking to enhance their R&D programs by leveraging all available clinical trial data sources.

Dr. Matt Zierhut and Nick Brown from Certara discuss how MBMA with CODEx Clinical Outcome database supports researchers’ go/no-go decision before a clinical trial in the article published on PHARMA FOCUS ASIA issued in September, 2023 (Issue No. 52).

You can download the interview article for free after filling in a web form.

ご視聴にはこちらからご登録ください
Powered by Translations.com GlobalLink Web Software